{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:51:02Z","timestamp":1790999462152,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>This study aimed to explore the cost-effectiveness of etanercept plus methotrexate (ETN+MTX) compared to triple disease-modifying anti-rheumatic drugs (DMARDs) in treating Chinese rheumatoid arthritis (RA) patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The 134 Chinese RA patients who were about to initiate ETN+MTX or triple DMARDs therapy based on treat-to-target strategy were consecutively recruited and categorized into ETN+MTX group (N\u200a=\u200a49) or triple DMARDs group (N\u200a=\u200a85). Treatment efficacy was assessed at month 3 (M3)\/M6\/M9\/M12 after initiation of treatment. Also, 1-year treatment cost was evaluated, and cost-effectiveness analysis and sensitivity analysis were conducted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>RA patients in ETN+MTX group exhibited similar disease activity and quality of life at each time point while elevated 28-joint disease activity score based on erythrocyte sedimentation rate (DAS28-ESR) change (M0-M12) and low disease activity rate compared with triple DMARDs group. For 1-year treatment cost, ETN+MTX required increased drug cost, decreased other medical cost, and finally elevated total cost compared with triple DMARDs. Meanwhile, compared to triple DMARDs, ETN+MTX produced an additional quality-adjusted life year (QALY) of 0.015, resulting in an incremental cost-effectiveness ratio (ICER) of \u00a52,939,506.7 per QALY that was 53.1 folds of gross domestic product (GDP) per capita in China. More interestingly, sensitivity analysis revealed that the ETN price had to be reduced at least by 71.3% before ETN+MTX became cost-effectiveness compared to triple DMARDs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>ETN+MTX is less cost-effective in treating Chinese RA patients compared with triple DMARDs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000016635","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T16:29:47Z","timestamp":1579192187000},"page":"e16635","source":"Crossref","is-referenced-by-count":13,"title":["Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients"],"prefix":"10.1097","volume":"99","author":[{"given":"Zhi-Chao","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Lishui People's Hospital, Lishui"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Ping","family":"Fei","sequence":"additional","affiliation":[{"name":"Department of Business Administration, Business School, East China University of Science and Technology, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Liang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Business Administration, Business School, East China University of Science and Technology, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,1]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"R4-20230915","first-page":"242","article-title":"2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis","volume":"57","author":"Chinese Rheumatology","year":"2018","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"Lancet"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","article-title":"New therapies for treatment of rheumatoid arthritis","volume":"370","author":"Smolen","year":"2007","journal-title":"Lancet"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/art.34498","article-title":"A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial","volume":"64","author":"Moreland","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1303006","article-title":"Therapies for active rheumatoid arthritis after methotrexate failure","volume":"369","author":"O\u2019Dell","year":"2013","journal-title":"N Engl J Med"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/acr.23255","article-title":"Rheumatoid arthritis treatment after methotrexate: the durability of triple therapy versus etanercept","volume":"69","author":"Peper","year":"2017","journal-title":"Arthritis Care Res"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3111\/13696998.2011.649327","article-title":"Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis","volume":"15","author":"Soini","year":"2012","journal-title":"J Med Econ"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1136\/ard.2004.032789","article-title":"Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial","volume":"64","author":"Kobelt","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/M16-0713","article-title":"Triple therapy versus biologic therapy for active rheumatoid arthritis: a cost-effectiveness analysis","volume":"167","author":"Bansback","year":"2017","journal-title":"Ann Intern Med"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.22895","article-title":"Cost-effectiveness of triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis","volume":"68","author":"Jalal","year":"2016","journal-title":"Arthritis Care Res"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"(5 Suppl 39)","key":"R16-20230915","first-page":"S93","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"23","author":"Fransen","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jval.2010.11.001","article-title":"Using HAQ-DI to estimate HUI-3 and EQ-5D utility values for patients with rheumatoid arthritis in Spain","volume":"14","author":"Carreno","year":"2011","journal-title":"Value Health"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/rheumatology\/kem115","article-title":"Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry","volume":"46","author":"Brennan","year":"2007","journal-title":"Rheumatology"},{"issue":"(Suppl 1)","key":"R20-20230915","doi-asserted-by":"crossref","first-page":"I65","DOI":"10.1136\/ard.58.2008.i65","article-title":"Etanercept: therapeutic use in patients with rheumatoid arthritis","volume":"58","author":"Garrison","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard.62.1.95","article-title":"Etanercept treatment of rheumatoid arthritis in the \u201creal world\u201d","volume":"62","author":"Smith","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/rheumatology\/kew264","article-title":"Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study","volume":"55","author":"Joensuu","year":"2016","journal-title":"Rheumatology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000016635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T23:18:40Z","timestamp":1694819920000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000016635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000016635","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}